Medically Trained Senior Executive/Board Member with Extensive Experience in Clinical Research and Drug Development
CARLSBAD, Calif.--(BUSINESS WIRE)--Apr. 22, 2021--
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced the appointment of Dr. Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH, DRCOG, DGM, to the Company’s Board of Directors, effective as of April 20, 2021. Dr. Amin is an experienced Non-Executive Director and a medically trained senior executive with broad expertise in medicine, pharmacology, healthcare, research, and product development. Dr. Amin has more than 26 years of experience within the pharmaceutical sector and is accomplished across diverse functional areas including clinical research, drug development, ethics and compliance, and commercial operations. She currently serves as a Non-Executive Director on the board of directors of Buckinghamshire Healthcare National Health Service Trust and the University of Hertfordshire in the UK.
“We are honored that Dr. Amin will be joining Lineage’s Board of Directors at this important time in the advancement of our mission to become the leading allogeneic cell transplant company,” stated Al Kingsley, Lineage’s Chairman of the Board. “Dr. Amin has had leadership responsibility for many aspects of pharmaceutical product development and clinical trials and has worked with numerous sponsors on countless product candidates while at Quintiles (now IQVIA). We believe her breadth of experience in clinical research and drug development, as well as her medical expertise and practical operational experience, will be particularly valuable to our Board and management team as Lineage continues to advance its three product candidates toward later stage clinical trials. We look forward to her support in guiding our corporate, product, and clinical strategy as we position ourselves for years of growth in the field of cell therapy.”
“Lineage’s clinical-stage programs and platform technologies have the potential to transform outcomes for patients suffering from serious medical conditions,” stated Dr. Amin. “I am excited about the opportunity to contribute to the Company’s future growth. I particularly look forward to helping guide the advancement of Lineage’s novel cell therapy product candidates toward later-stage clinical trials and the execution of other potentially valuable development activities, with an ultimate focus on transforming the lives of patients and creating value for the Company’s shareholders.”
Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH, DRCOG, DGM
Dipti Amin is an experienced Non-Executive Director and medically trained senior executive with a passion for high quality pharmaceutical research and healthcare, and extensive commercial, leadership, operational experience, in the private & public sectors, in medicine, pharmacology and the highly-regulated healthcare & research sectors, as well as compliance expertise. Over a span of more than 26 years, Dr. Amin has held positions of operational and strategic responsibility within Pharmaceutical Services at the C-suite and Board level, delivering consistently on growth, quality, customer, employee and process targets. Her broad experience covers Clinical Pharmacology, ethical issues in clinical research, drug development, ethics and compliance programs as well as leadership and management of large, multi-functional, multi-geography, global groups to deliver value-added, efficient growth and achieving business turnarounds. Dr. Amin has extensive international operational experience, including in the U.S., India, East Asia and Africa.
Dr. Amin spent more than 20 years at Quintiles Transnational (now IQVIA), the world’s largest provider of biopharmaceutical development & commercial outsourcing services. During her tenure, Dr. Amin served in a number of senior executive roles including: Compliance; Ethics & Quality; Drug Safety and Medical Affairs; Medical and Scientific Services; Regulatory Affairs, Medical Writing and Strategic Drug Development; and Clinical Development and Scientific Operations. Dr. Amin has successfully developed strategy and helped grow the P&L, sales & management for business units generating up to $600 million in revenue, while employing internationally based, multi-functional groups of highly qualified personnel. Dr. Amin is an Honorary Lecturer in Clinical Pharmacology at Guy’s, King’s, and St. Thomas’ Hospitals Medical & Dental Schools. Dr. Amin has also served on the Boards of Cambridge Innovation Capital and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, on the Innovation Board and Medical Expert Network of the Association of the British Pharmaceutical Industry, on a Department of Health Multi-centre Research Ethics Committee, on the Emerging Science and Bioethics Advisory Committee of the Dept. of Health, and on the Board of Governors of Heathfield School for Girls (The Girls’ Day School Trust).
Dr. Amin received her MB, BS (Bachelor of Medicine; Bachelor of Surgery) from Guys Hospital and St Thomas’ Hospitals (now GKT) Medical School in 1987. She holds the following certifications: DRCOG (Diploma of the Royal College of Obstetrics & Gynaecologists), DGM (Diploma in Geriatric Medicine of the Royal College of Physicians), MRCGP (Member of the Royal College of General Practitioners), DCH (Diploma in Child Health of the Royal College of Physicians), DCPSA (Diploma in Clinical Pharmacology), MFPM (Awarded Membership by Distinction of the Faculty of Pharmaceutical Medicine) and FFPM (Fellow of the Faculty of Pharmaceutical Medicine). Her clinical research work has been widely published in professional journals and textbooks, and she is a recognized presenter at international conferences.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Lineage’s clinical advancement of its three product candidates, Lineage’s potential growth in the field of cell therapy, the potential of Lineage’s clinical-stage programs and platform technologies to help patients, and Lineage’s positioning for future success. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks described in Lineage’s filings with the Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K filed with the SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005259/en/
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
Solebury Trout IR
Gitanjali Jain Ogawa
Russo Partners – Media Relations
Nic Johnson or David Schull
Source: Lineage Cell Therapeutics, Inc.